8 results on '"Harry Struijker-Boudier"'
Number of results to display per page
Search Results
2. Abridged version of the expert consensus document on arterial stiffness☆
- Author
-
Stephane Laurent, John Cockcroft, Luc Van Bortel, Pierre Boutouyrie, Cristina Giannattasio, Daniel Hayoz, Bruno Pannier, Charalambos Vlachopoulos, Ian Wilkinson, and Harry Struijker-Boudier
- Subjects
Artery ,Arterial stiffness ,Hemodynamics ,Pathophysiology ,Prognosis ,Cardiovascular events ,Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
In recent years great emphasis has been placed on the role of arterial stiffness in the development of cardiovascular diseases. The present article is an abridged version of an expert consensus document reporting the proceedings of several meetings of the European Network for Non Invasive Investigation of Large Arteries, and providing an updated and practical overview of the most relevant methodological aspects and clinical applications in this area. It provides recommendations for the determination of regional, local and systemic of arterial stiffness, and for the noninvasive determination of wave reflections. Clinical applications of arterial stiffness are also discussed.
- Published
- 2019
- Full Text
- View/download PDF
3. 2.1 COGNITION IN RELATION TO THE RETINAL MICROCIRCULATION IN CHILDREN BORN PREMATURELY OR AT TERM
- Author
-
Fangfei Wei, Anke Raaijmakers, Zhen-Yu Zhang, Theun Pieter van Tienoven, Qi-Fang Huang, Wen-Yi Yang, Lutgarde Thijs, Harry Struijker-Boudier, Peter Verhamme, Karel Allegaert, and Jan Staessen
- Subjects
Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: The retinal microvasculature can be visualized noninvasively and mirrors the status of the cerebral vasculature. We therefore investigated in 93 prematurely born infants (birth weight < 1000 g) and 87 controls born at term whether neurocognitive performance at ∼11 years is associated with the diameter of retinal microvessels. Methods: We post-processed retinal photographs by a semi-automated software (Singapore I Vessel Assessment, version 3.6) and administered the Wechsler Non-Verbal test, Dutch version (Pearson, The Netherlands) to estimate the intelligence quotient (IQ) by combining matrix reasoning and spatial span. Results: Compared with the controls, cases had lower IQ (92.5 vs. 108.7; P < 0.001), smaller central retinal arteriolar (CRAE; 162.7 vs. 174.0 mm; P < 0.001) and venular (CRVE; 234.7 vs. 242.7 mm; P = 0.003) diameters and CRAE/CRVE ratio (AVR; 0.70 vs. 0.72; P = 0.002) and lower body mass index (17.0 vs. 17.7 kg/m2; P = 0.044), but higher mean arterial pressure (82.7 vs. 77.7 mmHg; P < 0.001). In all children, the effect sizes associated with a 1-SD increase in CRAE were +3.87 (P < 0.001), +1.80 (P = 0.004) and +2.26 (P = 0.003) for total IQ, matrix reasoning, and spatial span, respectively. In models adjusted for body mass index and mean arterial pressure, these estimates were +3.21 (P = 0.009), +1.57 (P = 0.020), and +1.84 (P = 0.024), respectively. The associations of IQ and matrix reasoning with AVR also attained significance (P ≤ 0.031). Conclusions: In conclusion, our findings suggest that underdevelopment of the microcirculation in prematurely born children might have lasting effects on their cognitive performance.
- Published
- 2017
- Full Text
- View/download PDF
4. Should a statin be given to all hypertensive patients?
- Author
-
Harry Struijker-Boudier
- Subjects
Statin ,Hypertension ,Cardiovascular risk reduction ,Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Statins have become an essential treatment for primary and secondary prevention of cardiovascular risk. This has been firmly established for patients with a relatively high risk for cardiovascular complications. Recent studies, in particular the HOPE trial, has extended this observation to patients with intermediate cardiovascular risk, including hypertensive patients. On the other hand, statin use has been associated with side effects in a small percentage of patients. The decision to add a statin to the drug treatment of a hypertensive patient should be based on an assessment of the individual’s potential risk reduction and the perceived side effects of the treatment.
- Published
- 2017
- Full Text
- View/download PDF
5. Heart rate lowering treatment leads to a reduction in vulnerable plaque features in atherosclerotic rabbits.
- Author
-
Raf H M van Hoof, Evelien Hermeling, Judith C Sluimer, Julie Salzmann, Arnold P G Hoeks, Jérôme Roussel, Mat J A P Daemen, Harry Struijker-Boudier, Joachim E Wildberger, Sylvia Heeneman, and M Eline Kooi
- Subjects
Medicine ,Science - Abstract
To investigate the effect of a heart rate (HR) lowering agent (Ivabradine) on features of atherosclerotic plaque vulnerability with magnetic resonance imaging (MRI), ultrasound imaging, and histology.Atherosclerosis was induced in the abdominal aorta of 19 rabbits. Nine rabbits were treated with Ivabradine (17 mg/kg/day) during the entire study period. At week 14, imaging was performed. Plaque size was quantified on contrast-enhanced T1-weighted MR images. Microvascular flow, density, and permeability was studied with dynamic contrast-enhanced MRI. Plaque biomechanics was studied by measuring the aortic distension with ultrasound. After, animals were sacrificed and histology was performed. HR was reduced by 16% (p = 0.026) in Ivabradine-treated animals. No differences in absolute and relative vessel wall beat-to-beat distension were found, but due to the reduction in HR, the frequency of the biomechanical load on the plaque was reduced. Plaque size (MR and histology) was similar between groups. Although microvessel density (histology) was similar between groups, AUC and Ktrans, indicative for plaque microvasculature flow, density, and permeability, were decreased by 24% (p = 0.029) and 32% (p = 0.037), respectively. Macrophage content (relative RAM11 positive area) was reduced by 44% (p
- Published
- 2017
- Full Text
- View/download PDF
6. Artery 2014 symposium
- Author
-
Harry Struijker-Boudier
- Subjects
Arterial stiffness ,Drug treatment ,Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2016
- Full Text
- View/download PDF
7. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
- Author
-
Giuseppe, Mancia, Robert, Fagard, Krzysztof, Narkiewicz, Josep, Redon, Alberto, Zanchetti, Michael, Böhm, Thierry, Christiaens, Renata, Cifkova, Guy, De Backer, Anna, Dominiczak, Maurizio, Galderisi, Diederick E, Grobbee, Tiny, Jaarsma, Paulus, Kirchhof, Sverre E, Kjeldsen, Stéphane, Laurent, Athanasios J, Manolis, Peter M, Nilsson, Luis Miguel, Ruilope, Roland E, Schmieder, Per Anton, Sirnes, Peter, Sleight, Margus, Viigimaa, Bernard, Waeber, Faiez, Zannad, Michel, Burnier, Ettore, Ambrosioni, Mark, Caufield, Antonio, Coca, Michael Hecht, Olsen, Costas, Tsioufis, Philippe, van de Borne, Jose Luis, Zamorano, Stephan, Achenbach, Helmut, Baumgartner, Jeroen J, Bax, Héctor, Bueno, Veronica, Dean, Christi, Deaton, Cetin, Erol, Roberto, Ferrari, David, Hasdai, Arno W, Hoes, Juhani, Knuuti, Philippe, Kolh, Patrizio, Lancellotti, Ales, Linhart, Petros, Nihoyannopoulos, Massimo F, Piepoli, Piotr, Ponikowski, Juan Luis, Tamargo, Michal, Tendera, Adam, Torbicki, William, Wijns, Stephan, Windecker, Denis L, Clement, Thierry C, Gillebert, Enrico Agabiti, Rosei, Stefan D, Anker, Johann, Bauersachs, Jana Brguljan, Hitij, Mark, Caulfield, Marc, De Buyzere, Sabina, De Geest, Geneviève Anne, Derumeaux, Serap, Erdine, Csaba, Farsang, Christian, Funck-Brentano, Vjekoslav, Gerc, Giuseppe, Germano, Stephan, Gielen, Herman, Haller, Jens, Jordan, Thomas, Kahan, Michel, Komajda, Dragan, Lovic, Heiko, Mahrholdt, Jan, Ostergren, Gianfranco, Parati, Joep, Perk, Jorge, Polonia, Bogdan A, Popescu, Zeljko, Reiner, Lars, Rydén, Yuriy, Sirenko, Alice, Stanton, Harry, Struijker-Boudier, Charalambos, Vlachopoulos, Massimo, Volpe, David A, Wood, Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, Mancia, Giuseppe, Fagard, Robert, Narkiewicz, Krzysztof, Redon, Josep, Zanchetti, Alberto, Böhm, Michael, Christiaens, Thierry, Cifkova, Renata, De Backer, Guy, Dominiczak, Anna, Galderisi, Maurizio, Grobbee, Diederick E., Jaarsma, Tiny, Kirchhof, Paulu, Kjeldsen, Sverre E., Laurent, Stéphane, Manolis, Athanasios J., Nilsson, Peter M., Ruilope, Luis Miguel, Schmieder, Roland E., Sirnes, Per Anton, Sleight, Peter, Viigimaa, Margu, Waeber, Bernard, Zannad, Faiez, Burnier, Michel, Ambrosioni, Ettore, Caufield, Mark, Coca, Antonio, Olsen, Michael Hecht, Tsioufis, Costa, Van De Borne, Philippe, Zamorano, Jose Lui, Achenbach, Stephan, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Dean, Veronica, Deaton, Christi, Erol, Cetin, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ale, Nihoyannopoulos, Petro, Piepoli, Massimo F., Ponikowski, Piotr, Tamargo, Juan Lui, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Clement, Denis L., Gillebert, Thierry C., Rosei, Enrico Agabiti, Anker, Stefan D., Bauersachs, Johann, Hitij, Jana Brguljan, Caulfield, Mark, De Buyzere, Marc, De Geest, Sabina, Derumeaux, Geneviève Anne, Erdine, Serap, Farsang, Csaba, Funck Brentano, Christian, Gerc, Vjekoslav, Germano, Giuseppe, Gielen, Stephan, Haller, Herman, Jordan, Jen, Kahan, Thoma, Komajda, Michel, Lovic, Dragan, Mahrholdt, Heiko, Ostergren, Jan, Parati, Gianfranco, Perk, Joep, Polonia, Jorge, Popescu, Bogdan A., Reiner, Željko, Rydén, Lar, Sirenko, Yuriy, Stanton, Alice, Struijker Boudier, Harry, Vlachopoulos, Charalambo, Volpe, Massimo, and Wood, David A.
- Subjects
Male ,Systolic hypertension ,Medical Informatic ,Blood Pressure ,Guideline ,Retinal Disease ,chemistry.chemical_compound ,Electrocardiography ,Pregnancy ,Risk Factors ,Antihypertensive treatment ,Cardiovascular Disease ,Diabetes Complication ,Drug Interactions ,Metabolic Syndrome ,Brain Diseases ,Sleep Apnea, Obstructive ,Follow-up ,Metabolic Syndrome X ,Brain Disease ,Organ damage ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,Device therapy ,Antihypertensive Agent ,Heart Disease ,Drug Interaction ,Cardiovascular Diseases ,Echocardiography ,Cerebrovascular Disorder ,Hypertension ,Cardiology ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Ambulatory blood pressure ,Heart Diseases ,Hormone Replacement Therapy ,610 Medicine & health ,Risk Assessment ,Perioperative Care ,Diabetes Complications ,Young Adult ,Retinal Diseases ,Internal medicine ,Weight Loss ,medicine ,Humans ,Blood pressure measurement ,Renal Insufficiency, Chronic ,Exercise ,Physical Examination ,Perindopril/indapamide ,Antihypertensive Agents ,Aged ,Patient Care Team ,business.industry ,Platelet Aggregation Inhibitor ,Risk Factor ,Cardiovascular complication ,Hypertension, Pregnancy-Induced ,Aliskiren ,Cardiovascular risk ,Lifestyle ,medicine.disease ,Weight Lo ,Diet ,Candesartan ,Cerebrovascular Disorders ,Sexual Dysfunction, Physiological ,Blood pressure ,chemistry ,Heart failure ,Hyperglycemia ,Smoking Cessation ,Telmisartan ,business ,Delivery of Health Care ,Risk Reduction Behavior ,Medical Informatics ,Platelet Aggregation Inhibitors ,Contraceptives, Oral - Abstract
ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …
- Published
- 2013
8. N epsilon-(carboxymethyl)lysine during the early development of hypertension
- Author
-
Marcus, Baumann, Coen, Stehouwer, Jean, Scheijen, Uwe, Heemann, Harry, Struijker Boudier, and Casper, Schalkwijk
- Subjects
Glycation End Products, Advanced ,Oxidative Stress ,Heart Rate ,Creatinine ,Lysine ,Rats, Inbred SHR ,Hypertension ,Albuminuria ,Animals ,Humans ,Blood Pressure ,Rats, Inbred WKY ,Rats - Abstract
Advanced glycation end products (AGEs) are associated with hypertension. Whether N(epsilon)-(carboxymethyl)lysine (CML) contributes to the development of hypertension in young spontaneously hypertensive rats (SHR) remains to be established compared to WKY. We determined blood pressure, renal function, marker for oxidative stress (OS), and CML in young WKY rats and SHR. We found blood pressure was increased in SHR with no difference in renal function and OS compared to WKY. CML was elevated in plasma (2.3 +/- 0.3 vs. 1.3 +/- 0.2 micromol/L) and kidney (1.0 +/- 0.1 vs. 0.5 +/- 0.1 micromol/L) compared to WKY. Early CML accumulation may contribute to the development of hypertension potentially by inducing early renal inflammation independent of glomerular dysfunction or oxidative stress.
- Published
- 2007
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.